Insights Into Chronic Lymphocytic Leukemia (CLL)
Perspectives of community physicians on the treatment of CLL
Southwest – March 7, 2023
Faculty Chair
Mazyar Shadman, MD
Fred Hutchinson Cancer Center, Seattle, WA, USA
Southeast – March 11, 2023
Faculty Chair
Ryan Jacobs, MD
Atrium Health, Charlotte, NC, USA
Central #1 – March 25, 2023
Faculty Chair
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, USA
Central #2 – April 13, 2023
Faculty Chair
John Allan, MD
Weill Cornell Medicine, New York, NY, USA
Central #3 – April 22, 2023
Faculty Chair
Nitin Jain, MD
MD Anderson Cancer Center, Houston, TX, USA
East – May 4, 2023
Faculty Chair
John Allan, MD
Weill Cornell Medicine, New York, NY, USA
More Information
- Virtual series
- Southern California, Nevada, Utah, Arizona, New Mexico, Colorado
More Information
- Atlanta, GA
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
More Information
- Dallas, TX
- Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana
More Information
- Virtual Series
- Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana
More Information
- Dallas, TX
- Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana
More Information
- Virtual Series
- New York, Florida, Atlanta, New Jersey, Virginia
More Information
- Baltimore, MD
- Connecticut, Delaware, District of Columbia, Maine, Massachusetts, Maryland, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont
More Information
- Chicago, IL
- Illinois, Iowa, Minnesota, Nebraska, North Dakota, South Dakota, Wisconsin, Michigan, Indiana, Ohio
More Information
- Seattle, WA
- Northern California, Oregon, Washington, Idaho, Montana, Wyoming
REPORT SNAPSHOT
- A moderated roundtable discussion focusing on the treatment of CLL
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained: acalabrutinib, ibrutinib, zanubrutinib, obinutuzumab, rituximab, venetoclax, duvelisib, idelalisib, FCR, and BR
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region
